Chatbots are increasingly being recognized as valuable tools for clinical support in psychiatry. This study systematically evaluates their strengths and limitations in psychiatric clinical knowledge and reasoning. A total of 27 chatbots, including ChatGPT-o1-preview, were assessed using 160 multiple-choice questions derived from the 2023 and 2024 Taiwan Psychiatry Licensing Examinations. The Rasch model was employed to analyze chatbot performance, supplemented by dimensionality analysis and qualitative assessments of reasoning processes. Among the models, ChatGPT-o1-preview achieved the highest performance, with a JMLE ability score of 2.23, significantly exceeding the passing threshold (p < 0.001). It excelled in diagnostic and treatment reasoning and demonstrated a strong grasp of psychopharmacology concepts. However, limitations were identified in its factual recall, handling of niche topics, and occasional reasoning biases. Building on these findings, we have highlighted key aspects of a potential clinical workflow to guide the practical integration of chatbots into psychiatric practice. While ChatGPT-o1-preview holds significant potential as a clinical decision-support tool, its limitations underscore the necessity of human oversight. Continuous evaluation and domain-specific training are crucial to maximize its utility and ensure safe clinical implementation.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.